Background: 4 0 -Ethynyl-2-fluoro-2 0 -deoxyadenosine (EFdA) is a potent nucleoside analogue inhibitor of HIV that has an unusually long half-life. Cell culture selections with either EFdA or lamivudine using both subtype B and non-B clinical isolates selected the M184I/V substitutions in reverse transcriptase (RT). Unlike lamivudine, however, EFdA retained significant activity against viruses containing the M184I/V substitutions. In other clinical trials that evaluated rilpivirine together with emtricitabine in first-line therapy, the emergence of both the M184I/V and E138K mutations in RT was demonstrated. Moreover, the M184I/V and E138K substitutions were shown to be compensatory for each other with regard to both efficiency of RT activity and viral replicative capacity. This creates concern that E138K might emerge as a compensatory mutation for M184I/V in the aftermath of the use of EFdA.
Introduction
Recent results have shown that 4 0 -ethynyl-2-fluoro-2 0 -deoxyadenosine (EFdA) has the potential to be a safe and effective addition to the armamentarium of drugs that block replication of HIV. 1, 2 EFdA has been shown to be highly efficient in tissue culture and animals against both HIV and simian immunodeficiency virus (SIV) 1, [3] [4] [5] [6] and was also shown to have a very long half-life in HIVinfected individuals in Phase 1 efficacy studies. 5, 7 In rhesus macaques infected by SIV, EFdA was effective at reducing viral load when used as monotherapy and, moreover, no drug resistance mutations emerged in the reverse transcriptase (RT) coding region as a result of this exposure. 4 EFdA has also been shown to be effective against HIV RT-mediated chain elongation and this has been attributed to its ability to act as a translocation inhibitor, a novel mechanism of action for a nucleoside compound. 8, 9 Tissue culture studies have revealed that EFdA can select for the same M184I/V substitutions that confer .500-fold resistance to both lamivudine and emtricitabine. 10, 11 These same studies reported, by contrast, that M184I/V conferred only 2-to 10-fold resistance to EFdA. 2 This does not, in itself, create grounds for concern with regard to the potential clinical use of this compound, in part because M184I/V can compromise RT processivity and viral replicative capacity. 12, 13 A potential complicating factor, however, might be the emergence of compensatory mutation(s) that could, if present together with the M184I/V substitutions, increase levels of resistance to EFdA. One such substitution within the RT of HIV could be E138K, which confers modest-level resistance to several members of the NNRTI family of drugs, including rilpivirine, etravirine and dapivirine. [14] [15] [16] Multiple patients with viral loads .100000 copies of HIV RNA/mL who received rilpivirine, in combination with emtricitabine 17 This led to the recommendation that rilpivirine together with emtricitabine and tenofovir should not be used to initiate therapy in patients with viral loads .100000 copies of RNA/mL Several research groups investigated the potential reasons for the simultaneous presence of M184I/V and E138K in such patients. They showed using recombinant RT assays that M184I/V and E138K in combination could compensate for the impaired RT processivity that was conferred by either of these substitutions on its own. 12, 13 Tissue culture studies confirmed that an impairment in viral replication capacity that was conferred by either M184I/V or E138K alone was no longer detectable when both substitutions were simultaneously present. 12, 13 Therefore, a potential concern with regard to EFdA is that treatment could eventually give rise to the E138K substitution as well as M184I/V and that this combination might potentially be responsible for higher levels of HIV resistance to EFdA than those attributable to M184I/V alone, as well as restored viral replication capacity. For this reason, we investigated M184I/V and E138K, alone and in combination, to determine the levels of resistance that might be present in tissue culture to EFdA, lamivudine and rilpivirine.
Methods
HIV-1 NL4.3 -derived viral clones containing the desired mutations were made as described previously. 18 WT and mutant viruses were generated by transfection of proviral plasmid DNA into HEK293T cells. Drug susceptibilities of the viruses were measured by quantifying RT activity in cell culture phenotypic assays performed with cord blood mononuclear cells (CBMCs) as described previously. 19 Selection studies with EFdA and lamivudine were performed in CBMCs, using both subtype B and non-B clinical isolates from drug-naive patients as described previously. 14, 20 Weekly RT assays were performed on culture fluids to determine the extent of viral inhibition. Every week, the infected cells were co-cultured with fresh cells and the drug concentrations were adjusted appropriately to permit the emergence of resistant variants. At each passage, an aliquot of the supernatant was stored at -70 C for subsequent analysis. Viral RNA was extracted and sequenced to reveal genotypic changes in the RT gene.
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Results and discussion As summarized in Table 1 , resistance to EFdA and lamivudine arose through selection of the M184I or M184V substitution by weeks 14-27. The acquisition of lamivudine-selected M184I/V led to viral breakthrough and the ability to attain viral growth at very high lamivudine concentrations of 2.5 to .10 lM, i.e. .500 times the EC 50 . In contrast, EFdA retained significant activity against HIV since high drug concentrations could not be attained in these selections. It is noteworthy that E138K did not emerge in these selections at any time, even though this mutation has been shown to compensate for the loss in viral replication capacity conferred by M184I/V. Tissue culture selections with rilpivirine required 23-37 weeks until the first appearance of E138K ( Table 1) .
The results of phenotyping studies with various recombinant viruses are shown in Table 2 . EFdA inhibited HIV-1 replication in primary CBMCs with effective concentrations (EC 50 ) of 4 pM. This finding was consistent with the high potency of EFdA in primary PBMCs and MT-4 cells, with reported EC 50 values of 50 and 70 pM, respectively.
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The M184I and M184V substitutions in RT conferred far lower levels of resistance to EFdA than lamivudine, consistent with earlier reports. 10, 11 The EC 50 values for EFdA were 0.1 and 0.3 nM, respectively, as compared with 1 and 10 lM for lamivudine. The EC 50 potency of EFdA for viruses containing the E138K substitution together with either M184I or M184V were only slightly increased (3-fold) over those obtained with M184I or M184V alone. Our previous studies showed that the E138K mutation may modestly compensate for the deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. HIV drug resistance to EFdA JAC These findings are reassuring in that they suggest that EFdA will be resilient to the combined effects of M184I/V and E138K in tandem, even should E138K eventually emerge in the clinic in the aftermath of EFdA use alongside M184I/V as a compensatory mutation for RT enzymatic activity and viral replicative capacity. 18 The higher potency of EFdA, coupled with the 2 log-fold lower resistance conferred by M184I or M184V substitutions, suggests that this drug may be more resilient than lamivudine or emtricitabine in triple combination therapy, including rilpivirinebased regimens.
EFdA appears to be a truly robust agent that may have the best resistance profile of any NRTI developed to date. The findings of the current manuscript support the further clinical development of EFdA, which will hopefully lend itself to use in patients who are receiving HIV therapy for the first time as well as in treatment-experienced patients who have previously failed other therapies and who possess the M184I/V and other substitutions in RT that are associated with NRTI and NNRTI drug resistance. Oliveira et al.
